Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Aug 12, 2021 · 10-Q · 43 days after period end · 0001493152-21-019495
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$3.16M | -$733.41K | -$969.08K | -$1.21M |
| EPS Diluted | -$0.20 | -$0.13 | -$0.18 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end
